GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (ASX:IPD) » Definitions » EV-to-EBIT

Impedimed (ASX:IPD) EV-to-EBIT : -6.17 (As of Apr. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Impedimed EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Impedimed's Enterprise Value is A$146.45 Mil. Impedimed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.73 Mil. Therefore, Impedimed's EV-to-EBIT for today is -6.17.

The historical rank and industry rank for Impedimed's EV-to-EBIT or its related term are showing as below:

ASX:IPD' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.66   Med: -4.98   Max: 0.44
Current: -6.17

During the past 13 years, the highest EV-to-EBIT of Impedimed was 0.44. The lowest was -23.66. And the median was -4.98.

ASX:IPD's EV-to-EBIT is ranked worse than
100% of 466 companies
in the Medical Devices & Instruments industry
Industry Median: 19.7 vs ASX:IPD: -6.17

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Impedimed's Enterprise Value for the quarter that ended in Dec. 2023 was A$257.75 Mil. Impedimed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.73 Mil. Impedimed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.21%.


Impedimed EV-to-EBIT Historical Data

The historical data trend for Impedimed's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impedimed EV-to-EBIT Chart

Impedimed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.20 -1.62 -5.96 -3.15 -13.87

Impedimed Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.15 - -13.87 -

Competitive Comparison of Impedimed's EV-to-EBIT

For the Medical Devices subindustry, Impedimed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Impedimed's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Impedimed's EV-to-EBIT falls into.



Impedimed EV-to-EBIT Calculation

Impedimed's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=146.446/-23.728
=-6.17

Impedimed's current Enterprise Value is A$146.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Impedimed  (ASX:IPD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Impedimed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-23.728/257.74795
=-9.21 %

Impedimed's Enterprise Value for the quarter that ended in Dec. 2023 was A$257.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Impedimed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Impedimed EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Impedimed's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Impedimed (ASX:IPD) Business Description

Traded in Other Exchanges
Address
50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates most of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The Company recognizes revenue from stand alone sale of Legacy Devices and Consumables, Sale of SOZO Device and Software Subscription Services.

Impedimed (ASX:IPD) Headlines

No Headlines